Keyphrases
Mineralocorticoid Receptor Antagonists
100%
Cardiorenal Syndrome
100%
Steroidal
57%
Finerenone
42%
Kidney
28%
Chronic Kidney Disease
28%
Mineralocorticoid Receptor
28%
Esaxerenone
28%
Diabetic Nephropathy
14%
Adverse Outcomes
14%
Sodium
14%
High Risk
14%
Vasculature
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Fibrosis
14%
Japan
14%
Heart Failure
14%
Essential Hypertension
14%
High Specificity
14%
High Affinity
14%
Antifibrotic
14%
Clinical Assessment
14%
Hyperkalemia
14%
Disease-associated
14%
Pharmacodynamics
14%
Cardiovascular Events
14%
Phase II Trial
14%
Patients with Heart Failure
14%
Spironolactone
14%
End-organ Disease
14%
Pharmacokinetic Parameters
14%
Perceived Risk
14%
Renin-angiotensin-aldosterone System
14%
Disease Therapy
14%
Eplerenone
14%
Coregulators
14%
Physicochemical Parameters
14%
Development Assessment
14%
Anti-remodeling
14%
Kidney Events
14%
FIGARO
14%
FIDELIO-DKD
14%
Synergistic Treatment
14%
Medicine and Dentistry
Mineralocorticoid Antagonist
100%
Diseases
100%
Finerenone
42%
Chronic Kidney Disease
28%
Congestive Heart Failure
28%
Mineralocorticoid Receptor
28%
Esaxerenone
28%
Adverse Outcome
14%
Renin Angiotensin Aldosterone System
14%
Cardiovascular System
14%
Maturity Onset Diabetes of the Young
14%
Combination Therapy
14%
Diabetic Nephropathy
14%
Pharmacokinetics
14%
Fibrosis
14%
Vascularity
14%
Anti-Inflammatory Drug
14%
Hyperkalemia
14%
Pharmacodynamics
14%
Clinical Assessment
14%
Spironolactone
14%
Essential Hypertension
14%
Terminal Illness
14%
Eplerenone
14%
Phase III Trials
14%
Side Effect
14%
Pharmacology, Toxicology and Pharmaceutical Science
Mineralocorticoid Antagonist
100%
Diseases
100%
Finerenone
42%
Chronic Kidney Failure
28%
Congestive Heart Failure
28%
Mineralocorticoid Receptor
28%
Esaxerenone
28%
Renin
14%
Adverse Outcome
14%
Angiotensin
14%
Fibrosis
14%
Anti-Inflammatory Drug
14%
Combination Therapy
14%
Aldosterone
14%
Hyperkalemia
14%
Diabetic Nephropathy
14%
Pharmacokinetic Parameter
14%
Essential Hypertension
14%
Spironolactone
14%
Eplerenone
14%
Pharmacodynamic Parameter
14%
Phase III Trials
14%
Side Effect
14%
Maturity Onset Diabetes of the Young
14%